Amino acids, peptides and GLP-1: what “acids in Ozempic” means
The phrase “acids in Ozempic” is imprecise: Ozempic’s active ingredient is semaglutide, a modified peptide built from amino-acid units. It is not a mixture of free amino acids, not the body’s own GLP-1, and not the inactive ingredients in the pen. The EMA and U.S. label distinguish the active molecule, its GLP-1 analogue role and the formulation’s excipients.
Published: · Last reviewed:
This is an educational explanation of public product information, not treatment or dosing advice. Research products are for controlled laboratory research only and are not for human or veterinary use; they are not substitutes for authorised medicines.
Related research reading
The active ingredient is semaglutide
The EMA product information identifies semaglutide as a human GLP-1 analogue produced using recombinant DNA technology in yeast cells, and describes it as a GLP-1 receptor agonist with 94% sequence homology to human GLP-1. The U.S. DailyMed label describes specific chemical changes to the peptide backbone that support stability and prolonged action. An analogue is related to, but is not the same molecule as, endogenous GLP-1.
Amino-acid units are not the product excipients
Amino acids are the building units joined into semaglutide’s peptide chain. Separately, the medicine’s formulation contains excipients: the EMA lists disodium phosphate dihydrate, propylene glycol, phenol and water for injections in section 6.1. “Acids” should not be used to conflate the peptide’s amino-acid components with these inactive formulation ingredients.
Endogenous GLP-1, an analogue and a medicine differ
Endogenous GLP-1 is a naturally produced peptide signal; semaglutide is a chemically modified GLP-1 receptor agonist formulated as an authorised medicine. A research compound that is described as peptide-like or pathway-related is not automatically semaglutide, body-identical, equivalent to Ozempic or safe to use. Product labels describe the specific approved formulation—not all research materials.
Research references
- Ozempic: EPAR — Product information — European Medicines Agency, EMA product information, sections 2, 5.1 and 6.1
- OZEMPIC (semaglutide) injection — Prescribing information — DailyMed / U.S. National Library of Medicine, DailyMed set ID adec4fd2-6858-4c99-91d4-531f5f2a2d79, sections 11–12; updated June 2026
- The physiology of glucagon-like peptide 1 — Physiological Reviews / PubMed, PMID 17928588
Reference questions
Does Ozempic contain “acids” as its active ingredient?
The active ingredient is semaglutide, a modified peptide whose chain is built from amino-acid units. “Acids” alone is not a precise description of the active ingredient.
Are amino-acid building blocks the same as Ozempic’s excipients?
No. Amino-acid units form the semaglutide peptide. Excipients are separate formulation ingredients; the EMA lists them in section 6.1 of the product information.
Is semaglutide the same as the body’s GLP-1?
No. Regulatory information describes semaglutide as a modified GLP-1 analogue that acts at the GLP-1 receptor, not as the endogenous GLP-1 molecule itself.